DURHAM, N.C.--(BUSINESS WIRE)--Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced completion of patient enrollment in the intravascular ultrasound (IVUS) cohort of the randomized, controlled Tryton IDE Study evaluating the TRYTON Side Branch Stent for the treatment of bifurcation disease. Results of the multi-national Tryton IDE Study will be submitted to the U.S. Food and Drug Administration (FDA) for approval to market the device in the United States.
